hero section gradient
15 handpicked stocks

Biotech's IP Moat

This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.

Author avatar

Han Tan | Market Analyst

Published on July 11

Your Basket's Financial Footprint

Market capitalisation breakdown for 'Biotech's IP Moat' basket.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer tracking to broad market moves, reducing idiosyncratic risk.
  • Suitable as a core holding for diversified portfolios rather than a speculative, high-growth allocation.
  • Expect steadier long-term value; avoid anticipating explosive short-term gains.
Total Market Cap
  • MRNA: $10.74B

  • BNTX: $25.18B

  • CRSP: $6.58B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Patents are the crown jewels of biotech companies. Recent high-profile disputes between Pfizer, BioNTech, and Moderna highlight how valuable intellectual property is in this sector. Companies with strong patents can protect their innovations, command premium pricing, and generate licensing revenue for years.

2

What You Need to Know

This collection focuses on companies with "IP moats" - strong patent portfolios that protect their innovations from competitors. These stocks typically represent higher-risk, higher-reward investments in cutting-edge fields like gene editing, cell therapy, and RNA-based medicine, where breakthroughs can lead to substantial returns.

3

Why These Stocks

These companies were selected because they either have established intellectual property in revolutionary technologies or are developing the next generation of patentable breakthroughs. Their business models often depend on securing and defending foundational patents that can provide sustainable advantages in highly competitive markets.

Why You'll Want to Watch These Stocks

⚖️

The Patent Power Play

The Pfizer-Moderna lawsuit has put a spotlight on how valuable intellectual property can be in biotech. Companies that win these battles can secure billions in licensing fees or damages, creating massive shareholder value overnight.

🧬

Tomorrow's Breakthroughs Today

These companies aren't just developing treatments, they're creating entirely new ways to fight disease. Their groundbreaking platforms in gene editing and cell therapy could revolutionize medicine and generate huge returns for early investors.

🛡️

Built-in Competitive Protection

Strong patents act like a moat around a castle, keeping competitors at bay for years or even decades. This protection allows these companies to maintain premium pricing and higher profit margins than other sectors.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Drug Pricing Power | Major Pharma Stocks 2025

Drug Pricing Power | Major Pharma Stocks 2025

Following plans by major drugmakers to raise prices on hundreds of medications, the pharmaceutical industry is showcasing its significant pricing power. This development highlights an investment opportunity centered on established pharmaceutical companies capable of translating market dominance into revenue growth.

Automation & Software Investment Theme Overview

Automation & Software Investment Theme Overview

Recent labor data reveals a split market, with low private-sector jobless claims contrasting with high unemployment driven by federal layoffs. This dynamic creates an investment opportunity in companies providing automation, software, and efficiency-boosting services as businesses prioritize productivity over expanding their payrolls.

Oyo's IPO Plans: Hospitality Sector Recovery Explained

Oyo's IPO Plans: Hospitality Sector Recovery Explained

Global hospitality firm Oyo's parent company has revived its IPO plans, signaling renewed confidence in the travel market. This high-profile listing could ignite investor interest across the entire hospitality and travel technology sector, creating opportunities for related service providers.

Frequently Asked Questions